BETA DRUGS Financial Statement Analysis
|
||
|
The Revenues of BETA DRUGS have decreased by -100.00% YoY .
The Earnings Per Share (EPS) of BETA DRUGS has decreased by -2.19 % YoY. |
||
BETA DRUGS Last 5 Annual Financial Results
[NSE : BETA]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹362 Cr | ₹29,571,376 Cr | ₹0.00 Cr | ₹184 Cr | ₹116 Cr |
| Expenses | ₹288 Cr | ₹23,571,619 Cr | ₹0.00 Cr | ₹141 Cr | ₹91 Cr |
| Operating Profit (Excl OI) | ₹75 Cr | ₹5,999,757 Cr | ₹0.00 Cr | ₹43 Cr | ₹25 Cr |
| Other Income | ₹6.44 Cr | ₹135,889 Cr | ₹0.00 Cr | ₹0.76 Cr | ₹0.50 Cr |
| Interest | ₹6.99 Cr | ₹281,989 Cr | ₹0.00 Cr | ₹1.90 Cr | ₹2.42 Cr |
| Depreciation | ₹13 Cr | ₹978,227 Cr | ₹0.00 Cr | ₹7.25 Cr | ₹6.87 Cr |
| Profit Before Tax | ₹57 Cr | ₹4,875,430 Cr | ₹0.00 Cr | ₹34 Cr | ₹16 Cr |
| Profit After Tax | ₹42 Cr | ₹3,643,701 Cr | ₹0.00 Cr | ₹25 Cr | ₹12 Cr |
| Consolidated Net Profit | ₹42 Cr | ₹3,643,701 Cr | ₹0.00 Cr | ₹25 Cr | ₹12 Cr |
| Earnings Per Share (Rs) | ₹41.10 | ₹42.02 | ₹37.90 | ₹31.95 | ₹25.82 |
| PAT Margin (%) | 10.78 | 11.71 | 12.32 | 13.53 | 13.51 |
| ROE(%) | 18.78 | 23.95 | 26.03 | 28.55 | 30.85 |
| ROCE(%) | 19.16 | 25.23 | 32.74 | 33.94 | 36.38 |
| Total Debt/Equity(x) | 0.60 | 0.70 | 0.09 | 0.17 | 0.22 |
Key Financials |
||
| Market Cap | : | ₹ 1,909.8 Cr |
| Revenue (TTM) | : | ₹ 444.3 Cr |
| Net Profit(TTM) | : | ₹ 53.3 Cr |
| EPS (TTM) | : | ₹ 48.1 |
| P/E (TTM) | : | 35.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| BETA DRUGS | -13% | -17% | -5.2% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.8% | -2.1% | 4.8% |
| DIVIS LABORATORIES | 4.9% | 7.9% | 54.7% |
| TORRENT PHARMACEUTICALS | 1.6% | -2.7% | 28.1% |
| CIPLA | 2.4% | 3.4% | -12% |
| DR REDDYS LABORATORIES | 2.6% | 14.2% | 3.9% |
| MANKIND PHARMA | -0.3% | -2% | 2.9% |
| LUPIN | 2.1% | -0.8% | 3.9% |
| ZYDUS LIFESCIENCES | 5.7% | 8.2% | 23.8% |
BETA DRUGS Revenues
[NSE : BETA]
| Y-o-Y | -100.00 % |
| 5 Yr CAGR | 32.91 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹362 Cr | -100.00 | |
| Mar2025 | ₹29,571,376 Cr | 1,478,568,796,850.00 | |
| Mar2024 | ₹0.00 Cr | -100.00 | |
| Mar2023 | ₹184 Cr | 58.31 | |
| Mar2022 | ₹116 Cr | - | |
BETA DRUGS Operating Profit
[NSE : BETA]
| Y-o-Y | -100.00 % |
| 5 Yr CAGR | 31.77 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹75 Cr | -100.00 | |
| Mar2025 | ₹5,999,757 Cr | 599,975,652,400.00 | |
| Mar2024 | ₹0.00 Cr | -100.00 | |
| Mar2023 | ₹43 Cr | 72.57 | |
| Mar2022 | ₹25 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 1.48 % |
| 5 Yr CAGR | -0.86 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 20.59% | 1.48 | |
| Mar2025 | 20.29% | -59.42 | |
| Mar2024 | 50% | 115.24 | |
| Mar2023 | 23.23% | 9.01 | |
| Mar2022 | 21.31% | - | |
BETA DRUGS Profit After Tax
[NSE : BETA]
| Y-o-Y | -100.00 % |
| 5 Yr CAGR | 37.92 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹42 Cr | -100.00 | |
| Mar2025 | ₹3,643,701 Cr | 0 | |
| Mar2024 | ₹0.00 Cr | -100.00 | |
| Mar2023 | ₹25 Cr | 111.75 | |
| Mar2022 | ₹12 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -7.94 % |
| 5 Yr CAGR | -5.49 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 10.78 % | -7.94 | |
| Mar2025 | 11.71 % | -4.95 | |
| Mar2024 | 12.32 % | -8.94 | |
| Mar2023 | 13.53 % | 0.15 | |
| Mar2022 | 13.51 % | - | |
BETA DRUGS Earnings Per Share (EPS)
[NSE : BETA]
| Y-o-Y | -2.19 % |
| 5 Yr CAGR | 12.32 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹41 | -2.19 | |
| Mar2025 | ₹42 | 10.87 | |
| Mar2024 | ₹38 | 18.62 | |
| Mar2023 | ₹32 | 23.74 | |
| Mar2022 | ₹26 | - | |
BETA DRUGS Return on Capital Employed (ROCE)
[NSE : BETA]
| Y-o-Y | -24.06 % |
| 5 Yr CAGR | -14.81 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 19.16% | -24.06 | |
| Mar2025 | 25.23% | -22.94 | |
| Mar2024 | 32.74% | -3.54 | |
| Mar2023 | 33.94% | -6.71 | |
| Mar2022 | 36.38% | - | |
BETA DRUGS Share Price vs Sensex
| Current Share Price | : | ₹1,720.5 |
| Current MarketCap | : | ₹ 1,909.8 Cr |
| Updated EOD on | : | Nov 03,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BETA DRUGS | -13% |
-17% |
-5.2% |
| SENSEX | 4.5% |
6.1% |
-9.3% |
BETA DRUGS related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about BETA DRUGS Financials
How the annual revenues of BETA DRUGS have changed ?
The Revenues of BETA DRUGS have decreased by -100.00% YoY .
How the Earnings per Share (EPS) of BETA DRUGS have changed?
The Earnings Per Share (EPS) of BETA DRUGS has decreased by -2.19 % YoY .
Check out Intrinsic Value of Peers of BETA DRUGS
Compare Stock Analytics of Peers of BETA DRUGS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
